...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer
【24h】

Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer

机译:SIX1的过表达是I-III期大肠癌的独立预后标志物

获取原文
获取原文并翻译 | 示例

摘要

Epithelial-to-mesenchymal transition (EMT) contributes significantly to tumor progression and metastasis. The assessment of EMT-associated transcription factors could be a promising approach to identify biomarkers and potential therapeutic targets in colorectal cancer. In our study, we focused on the transcription factor Sine oculis homeobox (SIX) 1, which is a member of the superfamily of the homeobox genes and has been described to promote EMT in different types of tumors. Immunohistochemistry against SIX1 was performed on colorectal mucosa, adenomas, carcinomas-in situ and primary adenocarcinomas. An expression score was developed and subsequently assessed for its prognostic value in two independent cohorts. Cohort 1 consisted of 128 patients with stage I-III colorectal cancer; cohort 2 included 817 patients with stage I-III colorectal cancer who had participated in the DACHS study. HCT-116 cells were transfected with SIX1 plasmids and subjected to migration and colony formation assays. The expression of SIX1 increases gradually from mucosa to colorectal adenocarcinomas (p>0.0001). Univariate and multivariate analyses reveal that high expression of SIX1 is associated with decreased overall survival (cohort 1: HR: 4.01, CI: 1.20-14.07, p=0.025; cohort 2: HR: 1.43, CI: 1.014-2.02, p=0.047). Overexpression of SIX1 induces a more mesenchymal-like phenotype in HCT-116 cells and enhances tumor migration. High expression of SIX1 is an independent prognostic marker in colorectal cancer. It might be a promising biomarker to stratify patients into different risk groups. Moreover, targeting SIX1 might be a novel therapeutic approach in patients with colorectal cancer.
机译:上皮-间质转化(EMT)显着促进肿瘤的进展和转移。与EMT相关的转录因子的评估可能是鉴定大肠癌中生物标志物和潜在治疗靶标的有前途的方法。在我们的研究中,我们集中于转录因子正弦同源盒(Sine oculis homeobox,SIX)1,它是同源盒基因超家族的成员,并已被描述为在不同类型的肿瘤中促进EMT。针对大肠黏膜,腺瘤,原位癌和原发性腺癌进行了针对SIX1的免疫组织化学。开发了一个表达评分,随后在两个独立的队列中评估了其预后价值。队列1由128例I-III期大肠癌患者组成。队列2包括参与DACHS研究的817例I-III期大肠癌患者。用SIX1质粒转染HCT-116细胞,并进行迁移和集落形成分析。 SIX1的表达从粘膜到结直肠腺癌逐渐增加(p> 0.0001)。单因素和多因素分析显示SIX1的高表达与总生存期降低相关(队列1:HR:4.01,CI:1.20-14.07,p = 0.025;队列2:HR:1.43,CI:1.014-2.02,p = 0.047 )。 SIX1的过表达在HCT-116细胞中诱导出更接近间充质的表型,并增强了肿瘤的迁移。 SIX1的高表达是结直肠癌的独立预后指标。将患者分为不同的风险组可能是有前途的生物标志物。此外,靶向SIX1可能是结直肠癌患者的一种新型治疗方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号